FTC sues prescription-drug middlemen over insulin prices, says drugmakers are also 'on notice' Provided by Dow Jones Sep 20, 2024, 7:24:00 PM ...

FTC sues drug middlemen over manipulating the insulin market Caremark, Express Scripts and Optum Rx are accused of accepting money from drugmakers in exchange for keeping lower-cost insulin off ...

The Federal Trade Commission on Friday filed lawsuits against three prescription drug benefit managers or PBMs over concerns the companies are artificially inflating the list price of insulin drugs.

The FTC suit targets the three biggest so-called pharmacy benefit managers, UnitedHealth Group’s Optum Rx, CVS Health’s Caremark and Cigna’s Express Scripts.

The Federal Trade Commission said pharmacy benefit managers created a "perverse drug rebate system" that artificially inflated the cost of insulin.

The Federal Trade Commission on Friday sued three large U.S. health companies that negotiate insulin prices, arguing the drug middlemen boost their profits while "artificially" inflating costs for ...

The drug gatekeepers favored versions of insulin with higher upfront prices and bigger rebate payments from pharmaceutical companies, which shifted more costs onto patients, the FTC alleged.